Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

norethindrone acetate and ethinyl estradiol, ethinyl estradiol and ferrous fumarate

×

Overview

What is Lo Minastrin Fe?

Lo Minastrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets) provides an oral contraceptive regimen consisting of 24 blue, mint-flavored active chewable tablets and 2 white active tablets that contain the active ingredients, followed by 2 brown non-hormonal placebo tablets as specified below:

Each blue, active chewable tablet also contains the inactive ingredients mannitol, microcrystalline cellulose, FD&C Blue No. 1 Aluminum Lake, sodium starch glycolate, magnesium stearate, povidone, vitamin E, lactose monohydrate, spearmint flavor and sucralose.

Each white active tablet also contains the inactive ingredients mannitol, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, povidone, vitamin E and lactose monohydrate.

Each brown placebo tablet contains ferrous fumarate, mannitol, povidone, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, sucralose and spearmint flavor. The ferrous fumarate tablets do not serve any therapeutic purpose. Ferrous fumarate tablets do not meet USP criteria for dissolution and assay.

The chemical name of ethinyl estradiol is 19-Norpregna-1,3,5(10)-trien-20-yne-3, 17-diol, (17α). The empirical formula of ethinyl estradiol is CHO and the structural formula is:

     

The chemical name of norethindrone acetate is 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17α). The empirical formula of norethindrone acetate is CHO and the structural formula is:

     



What does Lo Minastrin Fe look like?



What are the available doses of Lo Minastrin Fe?

Lo Minastrin Fe consists of 28 tablets in the following order ():

What should I talk to my health care provider before I take Lo Minastrin Fe?

Nursing mothers: Not recommended; can decrease milk production ()

How should I use Lo Minastrin Fe?

Lo Minastrin Fe is indicated for use by females of reproductive age to prevent pregnancy . 

The efficacy of Lo Minastrin Fe in women with a body mass index (BMI) of more than 35 kg/m has not been evaluated.

To achieve maximum contraceptive effectiveness, Lo Minastrin Fe must be taken exactly as directed. Instruct patients to take one tablet by mouth at the same time every day. The blue tablet should be chewed and swallowed. The patient should drink a full glass (8 ounces) of water immediately after chewing and swallowing the blue tablet. The white tablet and the brown tablet are swallowed. Tablets must be taken in the order directed on the blister pack. Tablets should not be skipped or taken at intervals exceeding 24 hours. For patient instructions for missed tablets  . Lo Minastrin Fe may be administered without regard to meals .


What interacts with Lo Minastrin Fe?

Sorry No Records found


What are the warnings of Lo Minastrin Fe?

Sorry No Records found


What are the precautions of Lo Minastrin Fe?

Sorry No Records found


What are the side effects of Lo Minastrin Fe?

Sorry No records found


What should I look out for while using Lo Minastrin Fe?

Do not prescribe Lo Minastrin Fe to women who are known to have the following conditions:

Cigarette smoking increases the risk of serious cardiovascular

events

from

combination

oral contraceptive

(COC)

use. This risk increases with age

, particularly

in women over 35 years of

age

,

and with the number of cigarettes smoked

.

For this reason, COCs should not be used by w

omen who

are over 35 years of age and

smoke

 

[

see

]

.


What might happen if I take too much Lo Minastrin Fe?

There have been no reports of serious ill effects from overdose of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.


How should I store and handle Lo Minastrin Fe?

Product: 50436-3136NDC: 50436-3136-3 2 TABLET in a BOTTLENDC: 50436-3136-4 1 TABLET in a BOTTLEProduct: 50436-3136NDC: 50436-3136-3 2 TABLET in a BOTTLENDC: 50436-3136-4 1 TABLET in a BOTTLEProduct: 50436-3136NDC: 50436-3136-3 2 TABLET in a BOTTLENDC: 50436-3136-4 1 TABLET in a BOTTLE


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Non-Clinical Toxicology
Do not prescribe Lo Minastrin Fe to women who are known to have the following conditions:

Cigarette smoking increases the risk of serious cardiovascular

events

from

combination

oral contraceptive

(COC)

use. This risk increases with age

, particularly

in women over 35 years of

age

,

and with the number of cigarettes smoked

.

For this reason, COCs should not be used by w

omen who

are over 35 years of age and

smoke

 

[

see

]

.

Therapeutic doses of ticlopidine caused a 30% increase in the plasma half-life of antipyrine and may cause analogous effects on similarly metabolized drugs. Therefore, the dose of drugs metabolized by hepatic microsomal enzymes with low therapeutic ratios or being given to patients with hepatic impairment may require adjustment to maintain optimal therapeutic blood levels when starting or stopping concomitant therapy with ticlopidine. Studies of specific drug interactions yielded the following results:

Stop Lo Minastrin Fe if an arterial or deep venous thrombotic event (VTE) occurs. Stop Lo Minastrin Fe if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately.

If feasible, stop Lo Minastrin Fe at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of VTE.

Start Lo Minastrin Fe no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum VTE decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week.

The use of COCs increases the risk of VTE. However, pregnancy increases the risk of VTE as much or more than the use of COCs. The risk of VTE in women using COCs is 3 to 9 per 10,000 woman-years. The risk of VTE is highest during the first year of use of a COC. The risk of thromboembolic disease due to oral contraceptives gradually disappears after COC use is discontinued.

Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest in older (greater than 35 years of age), hypertensive women who also smoke. COCs also increase the risk for stroke in women with underlying risk factors.

Use COCs with caution in women with cardiovascular disease risk factors.

The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling:

Adverse reactions commonly reported by COC users are:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).